A New Chapter for Squamous Cell Lung Cancer: Harmoni’s Breakthrough at ASCO 2026

When the oncology world gathered in Chicago for the 2026 American Society of Clinical Oncology (ASCO) conference, the buzz wasn’t just about new checkpoints or CAR‑T cells. A modest‑sized booth bearing the AKESO logo drew a steady stream of curious clinicians, and for good reason: the company was ready to unveil data that could change the conversation around squamous‑cell lung cancer.

Squamous‑cell carcinoma, the historically tough‑to‑treat subset of non‑small cell lung cancer, has long lagged behind its adenocarcinoma cousin in terms of targeted options. That gap, AKESO believes, is finally narrowing. Their investigational combination—codenamed Harmoni—pairs an engineered bispecific antibody with a next‑generation PD‑1 inhibitor. The premise is simple yet elegant: coax the immune system to recognize cancer cells while simultaneously blocking the tumor’s escape routes.

The results, presented as a late‑stage Phase III trial involving 642 patients across 34 sites, were striking. Median overall survival jumped from 11.2 months in the control arm (standard chemotherapy) to 16.8 months with Harmoni. The hazard ratio of 0.68 translates to a 32 % reduction in the risk of death—a number that sparked a round of applause during the live session.

Equally important, the safety profile held up better than many had hoped. Grade 3 or higher adverse events occurred in 27 % of Harmoni recipients versus 35 % in the chemotherapy group. Most toxicities were manageable with standard supportive care, and treatment discontinuations were rare.

“These data are encouraging, especially for a patient population that has seen limited progress over the past decade,” said Dr. Maya Patel, lead investigator from the University of California, San Francisco. “If the findings hold up in the real‑world setting, Harmoni could become a new backbone for squamous‑cell disease.”

Beyond the numbers, the trial hinted at a possible biomarker story. Patients whose tumors expressed high levels of the novel target antigen seemed to derive the greatest benefit, opening the door to a more personalized approach.

AKESO’s CEO, Jonathan Ruiz, tempered optimism with realism. “We’re thrilled with the results, but we recognize the need for longer follow‑up and additional studies to confirm durability,” he said during the press briefing.

Looking ahead, the company plans to submit a New Drug Application to the FDA later this year, with hopes of launching Harmoni in 2027 if approval is granted. Meanwhile, oncologists worldwide will be debating how best to integrate this regimen into existing treatment algorithms.

For patients grappling with squamous‑cell lung cancer, the headline may finally read a little less bleak. As the data circulate through journals and conference halls, one thing is clear: the therapeutic landscape is shifting, and Harmoni could be a key piece of that transformation.